deltatrials
Completed PHASE3 NCT00316706

Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine

A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013

Sponsor: GlaxoSmithKline

Conditions Cervical Intraepithelial Neoplasia Papillomavirus Infection
Interventions GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) Havrix™
Updated 7 times since 2017 Last updated: Sep 13, 2012 Started: Oct 31, 2005 Primary completion: Jan 31, 2009 Completion: Jan 31, 2009

Listed as NCT00316706, this PHASE3 trial focuses on Cervical Intraepithelial Neoplasia and Papillomavirus Infection and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany, Bochum, Germany, Bogotá, Colombia, Brunsbüttel, Germany, Bützow, Germany, Comayagüela, Honduras, Deggingen, Germany, Ettenheim, Germany, Flensburg, Germany, Hamburg, Germany and 16 more location s